Benlysta

Active Ingredient(s): Belimumab
FDA Approved: * March 10, 2011
Pharm Company: * HUMAN GENOME SCIENCES INC.
Category: Immune System

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF),[4] also known as B-lymphocyte stimulator (BLyS).[5] It is approved in the United States,[6] Canada,[7] and the European Union[3] to treat systemic lupus erythematosus (SLE). The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection o... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
3 Discussions

Dosage List

Benlysta 120 mg/1.5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 12064-009
Labeler:
Glaxosmithkline Manufacturing Spa
Benlysta 400 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 12064-010
Labeler:
Glaxosmithkline Manufacturing Spa
Benlysta 200 mg/ml Subcutaneous Solution
NDC: 49401-088
Labeler:
Human Genome Sciences, Inc.
Benlysta 120 mg/1.5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 49401-101
Labeler:
Human Genome Sciences, Inc.
Benlysta 400 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 49401-102
Labeler:
Human Genome Sciences, Inc.

Popular Topics

Migraines associated to Benlysta use?

I am going for my fourth Benlysta treatment tomorrow and although I've noticed huge differences in my mobility and j...

10 REPLIES